# A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

Study · id `cardio:ct-nct06948422` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06948422](<https://clinicaltrials.gov/study/NCT06948422>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06948422

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 974 participants.

## Technical summary

Registry record NCT06948422. Randomized; double masking; primary purpose screening. Start 2025-04-30 (actual); primary completion 2027-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose screening
- Phase: Phase 3
- Enrolled: 974 participants (planned count; ClinicalTrials.gov record NCT06948422, source copy `cardio:ctgov-nct06948422-2026-05-29`, retrieved 2026-10-26)
- Started: 2025-04-30 (actual) (ClinicalTrials.gov record NCT06948422, source copy `cardio:ctgov-nct06948422-2026-05-29`, retrieved 2026-10-26)
- Primary completion: 2027-09 (anticipated) (ClinicalTrials.gov record NCT06948422, source copy `cardio:ctgov-nct06948422-2026-05-29`, retrieved 2026-10-26)
- Completion: 2027-09 (anticipated) (ClinicalTrials.gov record NCT06948422, source copy `cardio:ctgov-nct06948422-2026-05-29`, retrieved 2026-10-26)
- Countries: United States; Argentina; China; Czechia; Germany; Greece; India; Japan; Poland; Puerto Rico; Spain (ClinicalTrials.gov record NCT06948422, source copy `cardio:ctgov-nct06948422-2026-05-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06948422-2026-05-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
- Condition: Hypertension
- Intervention (Drug): Orforglipron
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: bf609dfc95c8502293a073ce141cf148ecfa938a691fee4ea47139e4dcf96022
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
